[HTML][HTML] A meta-analysis of erlotinib versus docetaxel for advanced nonsmall-cell lung cancer with poor prognosis
W Xu, C Jin, X Dai, X Lv - Indian Journal of Cancer, 2015 - journals.lww.com
Background: The extent of the benefit of erlotinib in the treatment of advanced nonsmall-cell
lung cancer (NSCLC) is still controversial when compared with docetaxel. This meta …
lung cancer (NSCLC) is still controversial when compared with docetaxel. This meta …
A meta-analysis of erlotinib versus docetaxel for advanced nonsmall-cell lung cancer with poor prognosis
W Xu, C Jin, X Dai, X Lv - Indian journal of cancer, 2015 - pubmed.ncbi.nlm.nih.gov
Background The extent of the benefit of erlotinib in the treatment of advanced nonsmall-cell
lung cancer (NSCLC) is still controversial when compared with docetaxel. This meta …
lung cancer (NSCLC) is still controversial when compared with docetaxel. This meta …
A meta-analysis of erlotinib versus docetaxel for advanced nonsmall-cell lung cancer with poor prognosis.
W Xu, C Jin, X Dai, X Lv - Indian Journal of Cancer, 2015 - europepmc.org
Background The extent of the benefit of erlotinib in the treatment of advanced nonsmall-cell
lung cancer (NSCLC) is still controversial when compared with docetaxel. This meta …
lung cancer (NSCLC) is still controversial when compared with docetaxel. This meta …
A meta-analysis of erlotinib versus docetaxel for advanced nonsmall-cell lung cancer with poor prognosis
W Xu, C Jin, X Dai, X Lv - Indian Journal of Cancer, 2015 - search.proquest.com
Background: The extent of the benefit of erlotinib in the treatment of advanced nonsmall-cell
lung cancer (NSCLC) is still controversial when compared with docetaxel. This meta …
lung cancer (NSCLC) is still controversial when compared with docetaxel. This meta …
A meta‑analysis of erlotinib versus docetaxel for advanced nonsmall‑cell lung cancer with poor prognosis.
W Xu, C Jin, X Dai, X Lv - Indian J Cancer, 2015 - pesquisa.bvsalud.org
BACKGROUND: The extent of the benefit of erlotinib in the treatment of advanced nonsmall‑
cell lung cancer (NSCLC) is still controversial when compared with docetaxel. This meta …
cell lung cancer (NSCLC) is still controversial when compared with docetaxel. This meta …
A meta-analysis of erlotinib versus docetaxel for advanced nonsmall-cell lung cancer with poor prognosis
W Xu, C Jin, X Dai, X Lv - Indian Journal of Cancer, 2015 - go.gale.com
Background: The extent of the benefit of erlotinib in the treatment of advanced nonsmall-cell
lung cancer (NSCLC) is still controversial when compared with docetaxel. This meta …
lung cancer (NSCLC) is still controversial when compared with docetaxel. This meta …
A meta-analysis of erlotinib versus docetaxel for advanced nonsmall-cell lung cancer with poor prognosis.
W Xu, C Jin, X Dai, X Lv, W Xu, C Jin… - Indian Journal of …, 2015 - search.ebscohost.com
Abstract < bold> Background: </bold> The extent of the benefit of erlotinib in the
treatment of advanced nonsmall-cell lung cancer (NSCLC) is still controversial when …
treatment of advanced nonsmall-cell lung cancer (NSCLC) is still controversial when …